Physician profile
Patrick Lam
NPI 1477538015
$14,042.78
in general payments reported to CMS, 2019-2025
22 companies · $2,017 in 2025
The $2,017 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,706 · 2020: $1,238 · 2021: $1,983 · 2022: $2,624 · 2023: $1,440 · 2024: $2,034 · 2025: $2,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,491.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,499.71 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, General - Therapies, 2cm Peripheral Cutting Balloon |
| Abbott Laboratories | $2,515.30 | 2020-2025 | Ensite, Na, Tacticath Ablation Catheter, Sensor Enabled |
| Sanofi-Aventis U.S. LLC | $1,306.81 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $881.18 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $657.87 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $587.12 | 2021-2025 | |
| Biotronik INC. | $322.51 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $271.15 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $255.17 | 2019-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $242.62 | 2021-2025 | Linq II, Micra |
| Phathom Pharmaceuticals, INC. | $96.29 | 2024 | Voquezna |
| Stereotaxis INC | $83.33 | 2022 | |
| Baylis Medical Company INC | $47.45 | 2021 | |
| Cardiva Medical, INC. | $44.57 | 2020-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Amgen INC. | $43.04 | 2019-2023 | Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.67 | 2022-2025 | Verquvo |
| Medtronic Vascular, INC. | $35.80 | 2019 | |
| Heartflow, INC. | $24.02 | 2025 | |
| Cordis US Corp. | $23.20 | 2025 | Mynx Control Venous |
| Kiniksa Pharmaceuticals International, Plc | $23.01 | 2024 | Arcalyst |
| Pfizer INC. | $21.61 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $21.35 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.